Project: Every Child for Younger Patients With Cancer

Recruiting now

Conditions studied: Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm

In brief

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Key facts

Study ID

NCT02402244

Run by

Children's Oncology Group

People needed

75000

Starts

2015-11-03

Expected to finish

2030-12-31

Last updated by the study team

2026-05-05

Who can join

Age: any, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem
• Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority
• Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
• All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)
• All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
• All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant
• The following other benign/borderline conditions:
• Mesoblastic nephroma
• Teratomas (mature and immature types)
• Myeloproliferative diseases including transient myeloproliferative disease
• Langerhans cell histiocytosis
• Lymphoproliferative diseases
• Desmoid tumors
• Gonadal stromal cell tumors
• Neuroendocrine tumors including pheochromocytoma
• Melanocytic tumors, except clearly benign nevi
• Ganglioneuromas
• Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit
• All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission
• If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1

Where it is running

• Dayton Children's Hospital — Dayton, Ohio, United States (enrolling)
• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States (enrolling)
• ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital — Toledo, Ohio, United States (enrolling)
• Legacy Emanuel Children's Hospital — Portland, Oregon, United States (enrolling)
• Oregon Health and Science University — Portland, Oregon, United States (enrolling)
• Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania, United States (enrolling)
• Natalie Warren Bryant Cancer Center at Saint Francis — Tulsa, Oklahoma, United States (enrolling)
• Geisinger Medical Center — Danville, Pennsylvania, United States (enrolling)
• Penn State Children's Hospital — Hershey, Pennsylvania, United States (enrolling)
• Drexel University School of Medicine — Philadelphia, Pennsylvania, United States (enrolling)
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (enrolling)
• Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania, United States (enrolling)
• Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania, United States (enrolling)
• Rhode Island Hospital — Providence, Rhode Island, United States (enrolling)
• Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
• Prisma Health Richland Hospital — Columbia, South Carolina, United States (enrolling)
• BI-LO Charities Children's Cancer Center — Greenville, South Carolina, United States (enrolling)
• Prisma Health Greenville Memorial Hospital — Greenville, South Carolina, United States (enrolling)
• Prisma Health Cancer Institute - Eastside — Greenville, South Carolina, United States (enrolling)
• Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota, United States (enrolling)
• T C Thompson Children's Hospital — Chattanooga, Tennessee, United States (enrolling)
• East Tennessee Childrens Hospital — Knoxville, Tennessee, United States (enrolling)
• Saint Jude Children's Research Hospital — Memphis, Tennessee, United States (enrolling)
• The Children's Hospital at TriStar Centennial — Nashville, Tennessee, United States (enrolling)
• Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.